Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application

NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news